Glycopeptides as Potential Interventions for COVID-19
Desalegn Getnet Demsie, 1 Abadi Kahsu Gebre, 1, 2 Ebrahim M Yimer, 1– 3 Niguse Meles Alema, 1 Ephrem Mebrahtu Araya, 1– 3 Abere Tilahun Bantie, 1– 4 Mengesha Dessie Allene, 1– 5 Hagazi Gebremedhin, 2 Adane Yehualaw, 6 Chernet Tafere, 6 Haileslassie Tesfay Tade...
Guardado en:
Autores principales: | Demsie DG, Gebre AK, Yimer EM, Alema NM, Araya EM, Bantie AT, Allene MD, Gebremedhin H, Yehualaw A, Tafere C, Tadese HT, Amare B, Weldekidan E, Gebrie D |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a3b4c34133c41f5938411eadae9e5a1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease
por: Mulaw Belete T
Publicado: (2020) -
CLÍNICA Y DIAGNÓSTICO SARS-COV-2
por: María Ester Pizarro
Publicado: (2020) -
Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant
por: Ravi Kant, et al.
Publicado: (2021) -
Hypercytokinemia and Pathogen–Host Interaction in COVID-19
por: Badawi A
Publicado: (2020) -
Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey
por: Ricarda Evens, et al.
Publicado: (2021)